CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
面向更准确的临床前胶质母细胞瘤建模：在胶质母细胞瘤小鼠模型中反向转化临床标准治疗
英文原题：Toward more accurate preclinical glioblastoma modeling: Reverse translation of clinical standard of care in a glioblastoma mouse model.
查看英文原题
Toward more accurate preclinical glioblastoma modeling: Reverse translation of clinical standard of care in a glioblastoma mouse model.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质母细胞瘤（GBM）是所有脑癌中最致命的。GBM患者接受包括手术、放疗和化疗在内的强化治疗方案，但这仅能适度延长患者生存期。因此，临床前研究正在测试新的实验性治疗。在此类临床前研究中，这些治疗在大多数情况下作为单一疗法给药；相反，在患者中，新治疗总是与标准治疗联合使用。最可能的是，这种差异导致了尽管临床前研究取得成功，临床试验却失败。在这项方法学研究中，我们详细展示了如何在临床前GBM研究中实施完整的临床标准治疗。系统性地测试新治疗，包括细胞免疫疗法，与临床标准治疗联合，可以更好地将临床前结果转化为临床，并最终提高患者生存期。
展开英文摘要原文
Glioblastoma (GBM) is the deadliest of all brain cancers. GBM patients receive an intensive treatment schedule consisting of surgery, radiotherapy and chemotherapy, which only modestly extends patient survival.
Therefore, preclinical studies are testing novel experimental treatments. In such preclinical studies, these treatments are administered as monotherapy in the majority of cases; conversely, in patients the new treatments are always combined with the standard of care. Most likely, this difference contributes to the failure of clinical trials despite the successes of the preclinical studies.
In this methodological study, we show in detail how to implement the full clinical standard of care in preclinical GBM research. Systematically testing new treatments, including cellular immunotherapies, in combination with the clinical standard of care can result in a better translation of preclinical results to the clinic and ultimately increase patient survival.
论文信息
- 作者
- Ziani-Zeryouh A、Wouters R、Thirion G、Vandenbrande K、Vankerckhoven A、Berckmans Y、Bevers S、Verbeeck J
- 第一作者单位
- Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.Belgium
- 通讯作者单位
- Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium. Electronic address: an.coosemans@kuleuven.be.Belgium
- 期刊
- Methods in cell biology2024
- 原文标识
- PubMed 38548420 · DOI 10.1016/bs.mcb.2023.07.003